Similar articles

• Adjuvant therapy for resectable colorectal carcinoma with 5-fluorouracil portal vein infusion.

  Cremona F, Izzo F, Ruffolo F, Palaia R, Parisi V. Cremona F, et al. J Chemother. 1997 Apr;9(2):140-1. doi: 10.1179/joc.1997.9.2.140. J Chemother. 1997. PMID: 9176762 Clinical Trial. No abstract available.
• Treatment of colorectal cancer.

  Påhlman L. Påhlman L. Ann Chir Gynaecol. 2000;89(3):216-20. Ann Chir Gynaecol. 2000. PMID: 11079791 Review. No abstract available.
• [Comparing the effect of adjuvant chemotherapy by portal vein infusion with intraluminal chemotherapy for colorectal cancer].

  Pan ZZ, Wan DS, Lu ZH, Li LR, Chen G, Zhou ZW, Wu XJ, Ding PR, Wang FL. Pan ZZ, et al. Zhonghua Wai Ke Za Zhi. 2004 Aug 7;42(15):918-21. Zhonghua Wai Ke Za Zhi. 2004. PMID: 15363253 Clinical Trial. Chinese.
• The AXIS colorectal cancer trial: randomization of over 2000 patients. The AXIS Steering Group.

  [No authors listed] [No authors listed] Br J Surg. 1994 Nov;81(11):1672. doi: 10.1002/bjs.1800811138. Br J Surg. 1994. PMID: 7827904 Clinical Trial. No abstract available.
• Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.

  Rougier P, Nordlinger B. Rougier P, et al. Ann Oncol. 1993;4 Suppl 2:21-8. doi: 10.1093/annonc/4.suppl_2.s21. Ann Oncol. 1993. PMID: 8353101 Review.